Endocrinology Drugs Market- By Therapy Type , , By Chemical Structure , By Organ/Gland Targeted , By End Use Industry, By Distribution Channel , By Geography - Global Opportunity Analysis & Industry Forecast, 2024-2030.
Endocrinology Drugs Market Overview:
Endocrinology Drugs Market size is estimated to reach $48 billion by 2030, growing at a CAGR of 7.8% during the forecast period 2024-2030. Endocrine drugs are medications used to treat conditions related to the endocrine system, a network of glands that produce hormones that regulate various bodily functions. These hormones travel through the bloodstream and signal specific organs and tissues to perform certain actions. Rising prevalence of endocrine disorders, growing geriatric population and the increasing investment in healthcare, are set to drive the growth of the global Endocrinology Drugs Market during the forecast period 2024-2030.
The shift towards personalized medicine and the growing demand for telemedicine and remote monitoring are major trends influencing the growth of the endocrinology market. Personalized medicine is an emerging practice that uses an individual's genetic makeup, environment, and lifestyle to tailor medical treatments and prevention strategies. This approach has the potential to improve the effectiveness of treatment and reduce side effects. The rise of telemedicine and remote monitoring technologies allows for continuous patient management making it easier to adjust treatment plans based on real-time data. These trends are set to have a favorable impact on the outlook of the endocrinology drugs industry throughout the forecast period.
Market Snapshot:
Endocrinology Drugs Market- Report Coverage:
The “Endocrinology Drugs Market Report - Forecast (2024-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Endocrinology Drugs Market.
Attribute | Segment |
---|---|
By Therapy Type |
· Hormone Replacement Therapy (HRT) · Hormone Suppression Therapy · Diabetes Medication · Others |
By Chemical Structure |
· Peptide Hormones · Steroids · Amino Acid Derivatives · Fatty Acid Derivatives (Eicosanoids) · Others |
By Organ/ Gland Type |
· Thyroid Gland · Pancreas · Adrenal Glands · Pituitary Gland · Parathyroid Glands · Reproductive Glands · Others |
By End Use Industry |
· Hospitals · Ambulatory Surgical Centers · Others |
By Distribution |
· Hospital Pharmacies · Retail Pharmacies · Online Pharmacies |
By Geography |
· North America (US, Canada and Mexico) · Europe (Germany, France, UK, Italy, Netherlands, Spain, Belgium and Rest of Europe) · Asia-Pacific (China, Japan, South Korea, India, Australia &Indonesia, Thailand, Malaysia and Rest of Asia-Pacific) · South America (Brazil, Argentina, Chile, Colombia and Rest of South America) · Rest of the World (Middle East and Africa). |
Impact of Covid and Russia Ukraine War:
The COVID-19 pandemic handicapped the global market extensively resulting in several challenges most notably, supply chain disruptions, but the pandemic caused an upsurge in the sales of the pharma industry. With increasing number of lifestyle diseases, there was a substantial demand for drugs during the pandemic, particularly diabetes medication. According to the American Diabetes Association, people with diabetes are more likely to have serious complications from COVID-19, especially if their diabetes is not well managed. Several online pharmacies experienced
record sales during the pandemic.
The ongoing Ukraine-Russia conflict's impact on Endocrinology Drugs is indirect. Disruptions in supply chains due to the conflict led to delays in shipments of these drugs. Additionally, geopolitical tensions affect the manufacturing and distribution of the product, causing fluctuations in market availability, pricing, and international trade dynamics within the industry.
Key Takeaways:
North America is the largest Market
Geographically, North America held the largest share with 37% of the overall market in 2023 and it is poised to dominate the market over the period 2024-2030. North America, particularly the United States, faces a high prevalence of conditions like diabetes, thyroid disorders, and obesity. According to the CDC’s (Centers for Disease Control) National Diabetes Statistics Report for 2022, cases of diabetes have risen to an estimated 37.3 million. 11.3% of the U.S. population has diabetes. According to Diabetes Canada, every 3 minutes one person in Canada is diagnosed with diabetes. This underscores the importance of endocrinology drugs in this region.
By Therapy Type, Diabetes is the largest Market
Diabetes is a global health crisis necessitating the use of insulin particularly in Type 1 diabetics. According to the IDF Annual Report 2022 prepared by the International Diabetes Federation (IDF), the number of people living with diabetes has more than
tripled since 2000, from 151 million to 537 million people in 2021. With over 141 million people with diabetes, China accounts for one in four people with the condition
worldwide. The increasing prevalence of diabetes drives the demand for endocrinology drugs including insulin and other glucose-lowering medications.
By Target Gland, Thyroid is expected to grow the fastest
Thyroid disease is a global health problem that can substantially impact well-being, particularly in pregnancy and childhood. In advanced economies, the prevalence of undiagnosed thyroid disease is falling owing to widespread thyroid function testing and relatively low thresholds for treatment initiation. According to NHS, Hypothyroidism, the most common thyroid disorder, typically requires lifelong hormone replacement therapy. This ongoing need for medication fuels market growth. According to a report of University of Aberdeen, one in 20 people in the UK have a thyroid problem, with women six times more likely to suffer from the condition than men.
Increase in Geriatric Population is Projected to Drive Market Growth
The geriatric population is predicted to reach 16% by 2050. US, Canada, Europe, India, and China are some regions where the geriatric population's growth is anticipated to witness rapid surges during the forecast period. For instance, with the decadal growth rate of the elderly population of India currently estimated to be at 41%, and the percentage of elderly population in the country projected to double to over 20% of total population by 2050, the United Nations Population Fund, India (UNFPA) in its 2023 India Ageing Report has said that by 2046 it is likely that elderly population will have surpassed the population of children (aged 0 to 15 years) in the country. The risk of diseases and disorders such as diabetes and cancer increase with age. The global diabetic population set to reach around 700 million by 2045, as per the International Diabetes Federation (IDF). Thus, the increase in the geriatric population is set to drive the endocrine drugs market.
Stringent Regulations
Stringent regulations in the Endocrinology Drugs market can delay access to new medications, especially for critical conditions. The thorough testing and evaluation required by regulatory agencies like the US Food and Drug Administration (FDA) can significantly delay the availability of new Endocrinology Drugs to patients. Compliance with these regulations involves extensive documentation, testing, and validation processes, which can be time-consuming and resource-intensive for manufacturers. Any deviation from regulatory requirements can result in delays, fines, or even product recalls, impacting market entry and business operations. Moreover, staying updated with evolving regulatory frameworks adds complexity to the process, further straining resources and hindering market access for both new entrants and established players.
Endocrinology Drugs Market: Market Share (%) by Region, 2023
For More Details on This Report - Request for Sample
Key Market Players:
The top 10 companies in the Endocrinology Drugs Market are:
- Johnson & Johnson
- Novo Nordisk A/S
- F. Hoffmann-La Roche AG
- GSK plc
- Pfizer Inc.
- Abbvie Inc.
- Bayer AG
- Sanofi S.A.
- Astrazeneca plc
- Novartis AG
Report Metric | Details |
---|---|
Market size available for years |
2023–2030 |
Base year considered |
2023 |
Forecast period |
2024–2030 |
Forecast units |
Value (USD) |
Segments covered |
Therapy Type, Chemical Structure, Organ/Gland Targeted, End Use Industry, Distribution Channel and Region |
Geographies covered |
North America (US, Canada and Mexico), Europe (Germany, France, UK, Italy, Netherlands, Spain, Belgium and Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia &Indonesia, Thailand, Malaysia and Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and Rest of South America), Rest of the World (Middle East and Africa). |
Companies covered |
Key 10 players covered include 1. Johnson & Johnson 2. Novo Nordisk A/S 3. F. Hoffmann-La Roche AG 4. GSK plc 5. Pfizer Inc. 6. Abbvie Inc. 7. Bayer AG 8. Sanofi S.A. 9. Astrazeneca plc 10. Novartis AG |
For more Lifesciences and Healthcare Market reports, please click here
1. Endocrinology Drugs Market- Market Overview
1.1 Definitions and Scope
2. Endocrinology Drugs Market - Executive Summary
2.1 Key Trends by Therapy Type
2.2 Key Trends by Chemical Structure
2.3 Key Trends by Organ/Gland Targeted
2.4 Key Trends by End Use Industry
2.5 Key Trends by Distribution
2.6 Key Trends by Geography
3. Endocrinology Drugs Market – Comparative analysis
3.1 Market Share Analysis- Major Companies
3.2 Product Benchmarking- Major Companies
3.3 Top 5 Financials Analysis
3.4 Patent Analysis- Major Companies
3.5 Pricing Analysis (ASPs will be provided)
4. Endocrinology Drugs Market - Startup companies Scenario Premium
4.1 Major startup company analysis:
4.1.1 Investment
4.1.2 Revenue
4.1.3 Product portfolio
4.1.4 Venture Capital and Funding Scenario
5. Endocrinology Drugs Market – Industry Market Entry Scenario Premium
5.1 Regulatory Framework Overview
5.2 New Business and Ease of Doing Business Index
5.3 Successful Venture Profiles
5.4 Customer Analysis – Major companies
6. Endocrinology Drugs Market - Market Forces
6.1 Market Drivers
6.2 Market Constraints
6.3 Porters Five Force Model
6.3.1 Bargaining Power of Suppliers
6.3.2 Bargaining Powers of Buyers
6.3.3 Threat of New Entrants
6.3.4 Competitive Rivalry
6.3.5 Threat of Substitutes
7. Endocrinology Drugs Market – Strategic Analysis
7.1 Value/Supply Chain Analysis
7.2 Opportunity Analysis
7.3 Product/Market Life Cycle
7.4 Distributor Analysis – Major Companies
8. Endocrinology Drugs Market – By Therapy Type (Market Size –$Million/$Billion)
8.1. Hormone Replacement Therapy (HRT)
8.1.1 Thyroid Hormones
8.1.2 Insulins
8.1.3 Sex Hormones
8.1.4 Corticosteroids
8.1.5 Growth Hormone
8.1.6 Others
8.2 Hormone Suppression Therapy
8.2.1 Anti-thyroid Drugs
8.2.2 Adrenal Suppressants
8.2.3 Anti-androgens
8.2.4 Growth Hormone Inhibitors
8.2.5 Prolactin Inhibitors
8.2.6 Others
8.3 Diabetes Medications
8.3.1 Insulins
8.3.2 Oral Hypoglycemics
8.3.3 Incretin Mimetics
8.3.4 Others
8.4 Others
9. Endocrinology Drugs Market- By Chemical Structure (Market Size –$Million/$Billion)
9.1 Peptide Hormones
9.2 Steroids
9.3 Amino Acid Derivatives
9.4 Fatty Acid Derivatives (Eicosanoids)
9.5 Others
10. Endocrinology Drugs Market –By Organ/Gland Targeted ((Market Size –$Million/$Billion))
10.1 Thyroid Gland
10.2 Pancreas
10.3 Adrenal Glands
10.4 Pituitary Gland
10.5 Parathyroid Glands
10.6 Reproductive Glands
10.7 Others
11. Endocrinology Drugs Market – By End Use Industry (Market Size –$Million/$Billion)
11.1 Hospitals
11.2 Ambulatory Surgical Centers
11.3 Others
12. Endocrinology Drugs Market – By Distribution Channel (Market Size –$Million/$Billion)
12.1 Hospital Pharmacies
12.2 Retail Pharmacies
12.3 Online Pharmacies
12.4 Specialty Pharmacies
13. Endocrinology Drugs Market - By Geography (Market Size -$Million/Billion)
13.1 North America
13.1.1 USA
13.1.2 Canada
13.1.3 Mexico
13.2 Europe
13.2.1 UK
13.2.2 Germany
13.2.3 France
13.2.4 Italy
13.2.5 Netherlands
13.2.6 Spain
13.2.7 Belgium
13.2.8 Rest of Europe
13.3 Asia-Pacific
13.3.1 China
13.3.2 Japan
13.3.3 India
13.3.4 South Korea
13.3.5 Australia
13.3.6 Indonesia
13.3.7 Thailand
13.3.8 Malaysia
13.3.9 Rest of APAC
13.4 South America
13.4.1 Brazil
13.4.2 Argentina
13.4.3 Colombia
13.4.4 Chile
13.4.5 Rest of South America
13.5 Rest of the World
13.5.1 Middle East
13.5.2 Africa
14. Endocrinology DrugsMarket – Entropy
14.1 New Product Launches
14.2 M&As, Collaborations, JVs and Partnerships
15. Endocrinology Drugs Market – Industry/Segment Competition Analysis
15.1 Company Benchmarking Matrix – Major Companies
15.2 Market Share at Global Level - Major companies
15.3 Market Share by Key Region - Major companies
15.4 Market Share by Key Country - Major companies
15.5 Market Share by Key Application - Major companies
15.6 Market Share by Key Product Type/Product category - Major companies
16. Endocrinology Drugs Market – Key Company List by Country Premium
17. Endocrinology Drugs Market Company Analysis - Business Overview, Product Portfolio, Financials, and Developments
17.1 Johnson & Johnson
17.2 Novo Nordisk A/S
17.3 F. Hoffmann-La Roche AG
17.4 GSK plc
17.5 Pfizer Inc.
17.6 Abbvie Inc.
17.7 Bayer AG
17.8 Sanofi S.A.
17.9 Astrazeneca plc
17.10 Novartis AG
"*Financials would be provided on a best-effort basis for private companies*”
Connect with our experts to get customized reports that best suit your requirements. Our reports include global-level data, niche markets and competitive landscape.
The Endocrinology Drugs Market is forecast to grow at 7.8% during the forecast period 2024 -2030
Global Endocrinology Drugs Market size is estimated to be US$ 29 billion in 2022 and is projected to reach US$ 48 Billion by 2030.
Johnson & Johnson, Novo Nordisk A/S, F. Hoffmann-La Roche AG, GSK plc, Pfizer Inc., Others.
The shift towards personalized medicine and the growing demand for telemedicine and remote monitoring are some of the trends in the Endocrinology Drugs market.
Rising prevalence of endocrine disorders, growing geriatric population and the increasing investment in healthcare are set to drive the growth of the global Endocrinology Drugs Market during the forecast period 2024-2030.